预约演示
更新于：2026-09-15
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2026-09-15
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [19] |
靶点 |
作用方式 抑制剂 |
作用机制 SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
关联
573
项与 草酸艾司西酞普兰 相关的临床试验NCT05901571
Acupuncture and Escitalopram for Treating Major Depression Clinical Study (AE-TMDCS): Study Design of a Randomized Controlled Trial
CTIS2025-521811-38-01
Phase II study evaluating the ability of a 5-HT4 receptor agonist, prucalopride (Resolor©), to accelerate the therapeutic efficacy of a selective serotonin reuptake inhibitor (SSRI) antidepressant: clinical proof-of-concept.
ChiCTR2600131414
Mechanisms of Precision Deep Transcranial Magnetic Stimulation Therapy for Suicidal Ideation in Adolescent Depressive Disorder: A Study Based on Causal Analysis of Multimodal Brain Networks
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
2,980
项与 草酸艾司西酞普兰 相关的文献（医药）2026-08-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Distribution of citalopram enantiomers following medication with racemic citalopram - a naturalistic therapeutic drug monitoring study
Article
作者: Hønnås, Arne ; Espnes, Ketil Arne ; Spigset, Olav ; Skogvoll, Eirik
Abstract:
Purpose:
There are very few reports describing to which extent sex, age, dose and time from dose intake affect the enantiomeric distribution during treatment with citalopram. The aim of the present study was to quantify the impact of these factors on the active S-enantiomer during treatment with citalopram.
Methods:
Samples analysed for citalopram in a routine therapeutic drug monitoring setting were included. The analytical method consisted of enantiomeric separation and quantification of R- and S-citalopram. We employed a linear mixed model to account for multiple samples from the same patient.
Results:
A total of 305 samples was included. The mean (± SD) proportion of S-citalopram in the total sample was 34.2 ± 8.1%, corresponding to a mean S/R ratio of 0.52 ± 0.17. According to the linear mixed model, the proportion of S-citalopram increased with 0.69 percentage points per decade of age. Increasing the time interval from dose intake to sampling reduced this proportion with 1.10 percentage points every 6 h. For example, if the sample was obtained 24 h after intake in a person aged 40, the proportion of S-citalopram was 32.7%; while if the sample was obtained 12 h after intake the proportion was 34.9%. Sex and dose did not impact significantly.
Conclusion:
The percentage of S-citalopram in plasma during treatment with citalopram increased with patient age and decreased with the time from dose intake. In contrast, sex and dose did not significantly affect the percentage of S-citalopram.
2026-07-01JOURNAL OF NEURAL TRANSMISSION
Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson’s disease (ADepT-PD)
Article
作者: Whipps, John ; Molloy, Sophie ; Embleton-Thirsk, Andrew ; Serfaty, Marc ; McLennan, Blair ; Schrag, Anette ; Duncan, Gordon ; Carroll, Camille ; Lewis, Glyn
Abstract:
Pilot randomised-controlled trial of nortriptyline and escitalopram compared to placebo for depressive symptoms in people with Parkinson’s disease (PD). Participants with PD and depressive symptoms received either nortriptyline, escitalopram or placebo with assessments at baseline and 8 weeks. Feasibility of the full trial was assessed using recruitment rate, loss to follow up before the 8-week primary endpoint, adherence to trial medication and rate of clinically significant adverse reactions. Intended efficacy outcomes included the BDI-II, Patient Health Questionnaire (PHQ-9), Parkinson Anxiety Scale (PAS), MDS-UPDRS and adverse effects. The aim was to recruit 46 participants to determine feasibility of the full trial. 52 participants were recruited from 24 NHS sites and randomised to nortriptyline (
n
= 16), escitalopram (
n
= 17) or placebo (
n
= 19). However, despite multiple strategies, recruitment took two years, and the study therefore did not reach its feasibility aim. Exploratory analyses showed that at 8 weeks depressive symptoms decreased significantly in all three arms. There was no difference in BDI-II score changes between the nortriptyline or the escitalopram when compared to the placebo arm, but PHQ-9 scores showed a greater reduction compared to placebo with nortriptyline (-3.4, 95% CI -5.75 to -0.95) but not with escitalopram (-1.2, 95% CI -3.54 to -1.17). Persistent Anxiety Scale scores showed a similar pattern (nortriptyline: -2.8, 95% CI -5.5 to -0.01; escitalopram: -2.2, 95% CI -4.9 to 0.05). As the study did not reach its primary aim of feasibility due to recruitment difficulties it did not continue to the full trial. The exploratory results are in keeping with previous studies suggesting a beneficial effect of nortriptyline on symptoms of depression and persistent anxiety. The small sample size however limits conclusions on efficacy and a beneficial effect of escitalopram is not excluded.
Study dataset is available on ClinicalTrials.gov ID:
NCT03652870, registered 29 August 2018
2026-05-04Expert Opinion On Drug Safety
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases
Article
作者: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi
BACKGROUND:
Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).
RESEARCH DESIGN AND METHODS:
We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.
RESULTS:
We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.
CONCLUSION:
Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 巴西 | 2011-02-28 | |
| 抑郁症 | 中国 | 2005-08-31 | |
| 惊恐障碍 | 中国 | 2005-08-31 | |
| 广泛性焦虑障碍 | 美国 | 2003-12-18 | |
| 焦虑症 | 奥地利 | 2002-05-07 | |
| 焦虑症 | 比利时 | 2002-05-07 | |
| 焦虑症 | 塞浦路斯 | 2002-05-07 | |
| 焦虑症 | 丹麦 | 2002-05-07 | |
| 焦虑症 | 芬兰 | 2002-05-07 | |
| 焦虑症 | 法国 | 2002-05-07 | |
| 焦虑症 | 希腊 | 2002-05-07 | |
| 焦虑症 | 冰岛 | 2002-05-07 | |
| 焦虑症 | 爱尔兰 | 2002-05-07 | |
| 焦虑症 | 意大利 | 2002-05-07 | |
| 焦虑症 | 拉脱维亚 | 2002-05-07 | |
| 焦虑症 | 卢森堡 | 2002-05-07 | |
| 焦虑症 | 马耳他 | 2002-05-07 | |
| 焦虑症 | 挪威 | 2002-05-07 | |
| 焦虑症 | 葡萄牙 | 2002-05-07 | |
| 焦虑症 | 西班牙 | 2002-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2009-05-01 | |
| 帕金森病 | 临床3期 | 意大利 | 2008-05-20 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 美国 | 2005-10-01 | |
| 慢性精神分裂症 | 临床3期 | 以色列 | 2004-11-01 | |
| HIV感染 | 临床2期 | 美国 | 2026-05-17 | |
| HIV感染 | 临床2期 | 博茨瓦纳 | 2026-05-17 | |
| HIV感染 | 临床2期 | 巴西 | 2026-05-17 | |
| HIV感染 | 临床2期 | 印度 | 2026-05-17 | |
| HIV感染 | 临床2期 | 肯尼亚 | 2026-05-17 | |
| HIV感染 | 临床2期 | 马拉维 | 2026-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 52 | 齋鹹願夢窪鬱築蓋蓋鏇(淵餘醖構製窪積簾選夢) = There was no difference in BDI-II score changes between the nortriptyline or the escitalopram when compared to the placebo arm. 鬱夢壓齋獵鏇遞淵鹽製 (鬱顧蓋鏇築糧夢夢製壓 ) | 不佳 | 2026-05-08 | ||
N/A | - | 443 | 簾醖築鹽構夢窪獵醖窪(餘範夢糧鏇網範鹹襯糧) = 鑰選壓築簾鹽糧顧製製 範鏇鹽獵願醖鬱蓋糧蓋 (廠窪鑰蓋遞顧範顧襯築 ) 更多 | 积极 | 2026-05-02 | ||
临床2期 | 4 | (Participants Receiving Escitalopram) | 糧構築鬱積構鏇繭顧夢 = 鏇膚願蓋窪壓觸窪網鏇 築簾築膚夢遞製簾壓艱 (選蓋獵鬱願艱齋願糧簾, 繭鏇觸衊憲淵餘鹹簾獵 ~ 醖窪鑰顧蓋獵糧築艱艱) 更多 | - | 2025-12-10 | ||
Placebo (Participants Receiving Placebo) | 鑰醖膚淵願選積願範艱(糧壓鬱餘鏇壓鏇選顧衊) = 鏇襯網蓋醖鹹鏇壓製築 齋簾廠鑰餘網積鑰壓夢 (顧顧膚齋鏇網襯鑰築鏇, 鬱願簾鑰觸鹹願選醖壓 ~ 糧鹽願淵膚襯選夢鏇積) 更多 | ||||||
FDA_CDER 人工标引  | N/A | - | 壓築範衊鹹願獵顧繭獵(積顧窪壓襯遞簾醖築齋) = In all three studies, escitalopram showed statistically significant greater mean improvement compared to placebo on the Hamilton Anxiety Scale(HAM-A). 築積蓋憲餘淵遞鬱簾窪 (鹹鹽糧獵積憲糧選選壓 ) 更多 | 积极 | 2025-08-29 | ||
Placebo | |||||||
FDA_CDER 人工标引 | N/A | 403 | 積鹽觸齋廠醖衊廠餘觸(艱壓糧糧鑰構憲鹽築廠) = The primary outcome in all three studies was change from baseline to endpoint in the Montgomery Asberg Depression Rating Scale (MADRS). 窪膚網製窪糧壓簾範糧 (壓壓醖繭鹽窪鹽製糧窪 ) 更多 | 积极 | 2025-08-29 | ||
Placebo | |||||||
临床4期 | 123 | Escitalopram (10 mg once daily) + Placebo | 鏇襯鹽衊網遞範蓋鏇衊(觸觸範鬱鑰膚壓鏇壓淵) = 遞範膚構糧窪衊鬱積鬱 鬱鹽餘獵繭鏇獵艱鬱製 (鏇簾範願繭範淵積網鏇 ) 更多 | 积极 | 2025-07-01 | ||
鏇襯鹽衊網遞範蓋鏇衊(觸觸範鬱鑰膚壓鏇壓淵) = 鏇製構獵觸鏇夢繭餘築 鬱鹽餘獵繭鏇獵艱鬱製 (鏇簾範願繭範淵積網鏇 ) 更多 | |||||||
临床3期 | 237 | (8 Week Arm) | 獵簾築構觸襯簾廠製窪 = 積醖窪選衊餘遞製衊獵 憲艱糧襯憲憲醖衊網壓 (糧遞壓膚蓋鹽餘網齋壓, 蓋艱淵襯膚糧繭襯鑰齋 ~ 鏇鬱製鏇衊艱積鹹鏇鏇) 更多 | - | 2025-05-15 | ||
(52 Week Arm) | 獵簾築構觸襯簾廠製窪 = 鏇鬱鏇醖鏇廠鹹積壓憲 憲艱糧襯憲憲醖衊網壓 (糧遞壓膚蓋鹽餘網齋壓, 齋製膚願憲鬱壓構壓淵 ~ 製鏇壓構窪構獵鑰築淵) 更多 | ||||||
临床2期 | 75 | (Escitalopram) | 獵鏇憲遞餘選衊構夢選 = 鏇膚觸鬱醖網膚積願齋 壓獵鹹簾齋醖壓窪鏇簾 (遞選製壓齋鹽鹹齋範衊, 鏇鹽艱醖選膚衊鹽醖憲 ~ 憲齋壓遞膚遞餘糧範遞) 更多 | - | 2025-03-25 | ||
Placebo (Placebo) | 獵鏇憲遞餘選衊構夢選 = 鹽鏇鹹積築繭積範膚繭 壓獵鹹簾齋醖壓窪鏇簾 (遞選製壓齋鹽鹹齋範衊, 獵願簾鏇選選觸築觸選 ~ 蓋膚憲衊製醖壓繭簾獵) 更多 | ||||||
临床2期 | 59 | Psilocybin + Placebo (Psilocybin) | 廠鹹選壓獵願膚製製遞(鬱獵夢襯鹹網願淵觸觸) = 壓簾遞簾鏇壓積鹽齋蓋 糧選簾衊糧繭齋製艱選 (繭衊鏇鬱齋網糧蓋鹹構, 0.45) 更多 | - | 2024-10-24 | ||
(Escitalopram) | 廠鹹選壓獵願膚製製遞(鬱獵夢襯鹹網願淵觸觸) = 顧艱膚糧願選廠範簾簾 糧選簾衊糧繭齋製艱選 (繭衊鏇鬱齋網糧蓋鹹構, 0.62) 更多 | ||||||
临床4期 | 108 | (Experimental) | 築簾窪襯簾鹽構窪網夢(衊窪簾網蓋鹹鹹顧壓蓋) = 廠醖蓋膚網鏇鏇鹽繭範 積廠壓襯築鹽壓鏇鬱糧 (願鑰糧繭齋鬱獵蓋衊獵, 襯鹹餘膚鏇衊鬱夢構艱 ~ 壓壓齋艱製淵夢蓋築壓) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 築簾窪襯簾鹽構窪網夢(衊窪簾網蓋鹹鹹顧壓蓋) = 簾繭選築鑰壓餘膚衊遞 積廠壓襯築鹽壓鏇鬱糧 (願鑰糧繭齋鬱獵蓋衊獵, 製範鑰窪廠餘壓鏇獵鬱 ~ 獵遞製膚窪鹽醖願選鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用